Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS

Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS

It has been stated that developing a drug that can attack mutated RAS proteins is ‘the Holy Grail’ of cancer therapeutics. Through a series of unexpected findings, the authors discovered that the irreversible epidermal growth factor receptor 1/2/4 inhibitor neratinib (HKI-272, Nerlynx®) was not only...

Full description

Bibliographic Details
Main Authors: Paul Dent, Andrew Poklepovic, Laurence Booth
Format: Article
Language:English
Published: European Medical Journal 2019-11-01
Series:European Medical Journal Oncology
Subjects:
hippo
histone deacetylase (hdac) inhibitor
neratinib
ras
sildenafil
yes-associated protein (yap)
statin
Online Access:https://www.emjreviews.com/oncology/article/discovery-of-a-grail-shaped-drug-ne-ratinib-and-the-downregulation-of-mutant-ras/

Internet

https://www.emjreviews.com/oncology/article/discovery-of-a-grail-shaped-drug-ne-ratinib-and-the-downregulation-of-mutant-ras/

Similar Items